BTK and Waldenstrom macroglobulinemia: The most studied BTK inhibitor is ibrutinib (PCI-32765), approved for CLL, Waldenström’s macroglobulinemia, mantle cell lymphoma (MCL) (second line), marginal zone lymphoma, and chronic graft-vs-host disease [123–127].